文献速递造血干细胞移植与细胞治疗

受者与供者遗传变异与异基因造血细胞移植后死亡率的相关性

Recipient and donor genetic variants associated with mortality after allogeneic hematopoietic cell transplantation.
PubMed 文献 · Blood Adv · 2020-01-01

研究在2560例欧洲血统相关或无关供者HCT受者中检测122个受者与供者候选变异与NRM及RM的关联,并在1710例独立队列中验证。发现供者MICA基因rs1051792 A等位基因与较低NRM风险相关,供者MICA-129Met与3-4级GVHD及伴3-4级GVHD患者的NRM风险降低相关;其他候选变异及全基因组关联分析未发现与NRM或RM相关的变异。

要点

  • 供者MICA rs1051792 A等位基因与较低的非复发死亡率风险相关。
  • 供者MICA-129Met与3-4级GVHD及伴3-4级GVHD患者的NRM风险降低相关,MICA-129Val无此关联。
  • 其他候选变异及全基因组关联分析未发现与NRM或RM相关的变异。

核心结论

  • 供者MICA rs1051792 A等位基因与较低NRM风险相关,供者MICA-129Met可能解释HCT后NRM风险降低。
  • 其他候选变异及全基因组关联分析未发现与NRM或RM相关的变异。

研究设计与样本

  • 在2560例欧洲血统相关或无关供者HCT受者队列中检测122个受者与供者候选变异与NRM及RM的关联。
  • 发现的关联在1710例HCT受者的独立队列中进行验证。

主要发现

  • 供者MICA rs1051792 A等位基因与较低NRM风险相关。
  • 供者与受者rs1051792基因型高度相关,统计学上无法确定关联来自供者还是受者基因型。
  • 供者MICA-129Met时3-4级GVHD风险及伴3-4级GVHD患者的NRM风险较低,MICA-129Val无此关联。
  • 候选变异分析未显示其他与NRM或RM的关联,全基因组关联分析未识别其他与NRM或RM相关的变异。

局限性

  • 原文指出供者与受者rs1051792基因型高度相关,统计学上无法确定关联来自供者还是受者基因型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Many studies have suggested that genetic variants in donors and recipients are associated with survival-related outcomes after allogeneic hematopoietic cell transplantation (HCT), but these results have not been confirmed. Therefore, the utility of testing genetic variants in donors and recipients for risk stratification or understanding mechanisms leading to mortality after HCT has not been established. We tested 122 recipient and donor candidate variants for association with nonrelapse mortality (NRM) and relapse mortality (RM) in a cohort of 2560 HCT recipients of European ancestry with related or unrelated donors. Associations discovered in this cohort were tested for replication in a separate cohort of 1710 HCT recipients. We found that the donor rs1051792 A allele in MICA was associated with a lower risk of NRM. Donor and recipient rs1051792 genotypes were highly correlated, making it statistically impossible to determine whether the donor or recipient genotype accounted for the association. Risks of grade 3 to 4 graft-versus-host disease (GVHD) and NRM in patients with grades 3 to 4 GVHD were lower with donor MICA-129Met but not with MICA-129Val, implicating MICA-129Met in the donor as an explanation for the decreased risk of NRM after HCT. Our analysis of candidate variants did not show any other association with NRM or RM. A genome-wide association study did not identify any other variants associated with NRM or RM.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Martin PJ, Levine DM, Storer BE, et al. Recipient and donor genetic variants associated with mortality after allogeneic hematopoietic cell transplantation. Blood Adv. 2020. PMID: 32687560. doi:10.1182/bloodadvances.2020001927

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。